Iovance Biotherapeutics, Inc.
14.09USD
-0.0500 (-0.35%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on IOVA.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.09▲ | -$0.12 | 2 | 0 |
| Next quarter | -$0.08▲ | -$0.12 | 2 | 0 |
| Current year | -$0.45▲ | -$0.56 | 5 | 0 |
| Next year | -$0.2▲ | -$0.32 | 5 | 0 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.13 | -$0.11 | +0.02 (+18.4%) |
| 2026-03-31 | -$0.15 | -$0.19 | -0.04 (-23.8%) |
| 2025-12-31 | -$0.18 | -$0.18 | -0.00 (-2.1%) |
| 2025-09-30 | -$0.26 | -$0.25 | +0.01 (+2.8%) |
157 ratings from 18 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $15 $18 | Oct 13, 2026 |
| Baird | Maintained | Neutral | $6 $11 | Oct 8, 2026 |
| Wells Fargo | Maintained | Overweight | $14 $18 | Sep 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $9 $20 | Sep 29, 2026 |
| Barclays | Maintained | Overweight | $13 $15 | Sep 17, 2026 |
| TD Cowen | Maintained | Buy | $7 $10 | Aug 25, 2026 |
| UBS | Maintained | Neutral | $4 $7 | Aug 20, 2026 |
| Mizuho | Maintained | Outperform | $10 $11 | Aug 18, 2026 |
| Barclays | Maintained | Overweight | $11 $13 | Aug 7, 2026 |
| Citizens | Maintained | Market Outperform | $5 $8 | Aug 7, 2026 |
| Chardan Capital | Maintained | Buy | $16 $14 | May 8, 2026 |
| Chardan Capital | Maintained | Buy | $16 | Apr 10, 2026 |
| UBS | Maintained | Neutral | $2 $4 | Mar 5, 2026 |
| Citizens | Upgraded from Market Perform | Market Outperform | $5 | Mar 3, 2026 |
| Barclays | Maintained | Overweight | $10 $11 | Feb 25, 2026 |
| Citizens | Upgraded from Market Perform | Market Outperform | $5 | Feb 25, 2026 |
| Barclays | Maintained | Overweight | $9 $10 | Dec 17, 2025 |
| Barclays | Maintained | Overweight | $4 $9 | Nov 24, 2025 |
| Chardan Capital | Maintained | Buy | $20 $17 | Nov 6, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20 $9 | Oct 29, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Aug 19, 2025 |
| Wells Fargo | Maintained | Overweight | $18 $14 | Aug 8, 2025 |
| Chardan Capital | Maintained | Buy | $25 $20 | Aug 8, 2025 |
| Chardan Capital | Maintained | Buy | $25 | Jul 23, 2025 |
| UBS | Downgraded from Buy | Neutral | $17 $2 | May 16, 2025 |
80 filings from 12 insiders · 0 buy / 0 sell over 6m
Officers and directors of IOVA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Berkowitz NoahOfficer, Chief Medical Officer | GrantPerformance Stock Units | 135.0k | — | — | Sep 30, 2026 |
| Berkowitz NoahOfficer, Chief Medical Officer | GrantRestricted Stock Units | 180.0k | — | — | Sep 30, 2026 |
| Berkowitz NoahOfficer, Chief Medical Officer | GrantStock Options (Right to Buy) | 135.0k | — | — | Sep 30, 2026 |
| Vogt Frederick GDirector; Officer, Interim CEO & General Counsel | ExerciseRestricted Stock Units | 15.6k | — | — | Sep 8, 2026 |
| Vogt Frederick GDirector; Officer, Interim CEO & General Counsel | Tax | 6.6k | $8.70 | $58k | Sep 8, 2026 |
| Vogt Frederick GDirector; Officer, Interim CEO & General Counsel | Exercise | 15.6k | — | — | Sep 8, 2026 |
| BILINSKY IGOROfficer, Chief Operating Officer | ExerciseRestricted Stock Units | 7.8k | — | — | Sep 8, 2026 |
| BILINSKY IGOROfficer, Chief Operating Officer | Tax | 4.0k | $8.70 | $35k | Sep 8, 2026 |
| BILINSKY IGOROfficer, Chief Operating Officer | Exercise | 7.8k | — | — | Sep 8, 2026 |
| Puri Raj K.Officer, Chief Regulatory Officer | ExerciseRestricted Stock Units | 9.8k | — | — | Sep 8, 2026 |
| Puri Raj K.Officer, Chief Regulatory Officer | Tax | 4.5k | $8.70 | $39k | Sep 8, 2026 |
| Puri Raj K.Officer, Chief Regulatory Officer | Exercise | 9.8k | — | — | Sep 8, 2026 |
| Vogt Frederick GDirector; Officer, Interim CEO & General Counsel | ExerciseRestricted Stock Units | 41.7k | — | — | Sep 1, 2026 |
| Vogt Frederick GDirector; Officer, Interim CEO & General Counsel | Tax | 17.7k | $8.28 | $147k | Sep 1, 2026 |
| Vogt Frederick GDirector; Officer, Interim CEO & General Counsel | Exercise | 41.7k | — | — | Sep 1, 2026 |
| Puri Raj K.Officer, Chief Regulatory Officer | ExerciseRestricted Stock Units | 5.5k | — | — | Sep 1, 2026 |
| Puri Raj K.Officer, Chief Regulatory Officer | Tax | 2.5k | $8.28 | $21k | Sep 1, 2026 |
| Puri Raj K.Officer, Chief Regulatory Officer | Exercise | 5.5k | — | — | Sep 1, 2026 |
| BILINSKY IGOROfficer, Chief Operating Officer | ExerciseRestricted Stock Units | 8.8k | — | — | Sep 1, 2026 |
| BILINSKY IGOROfficer, Chief Operating Officer | Tax | 4.5k | $8.28 | $37k | Sep 1, 2026 |
No analyst notes on IOVA yet.
Analyst Ratings
10 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 6 | 2 | 0 | 0 | Buy2.00 |
| 1 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |
| 2 mo ago | 2 | 5 | 2 | 0 | 0 | Buy2.00 |
| 3 mo ago | 2 | 5 | 2 | 0 | 0 | Buy2.00 |
Members whose judged calls on IOVA have played out most reliably.
No settled calls on IOVA yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice